Stay updated on Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page.

Latest updates to the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page
- Check2 days agoChange DetectedThe page revision was bumped from v3.6.4 to v3.6.5. This indicates a minor update to the page build rather than changes to study content or user-facing features.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoChange DetectedThe page revision tag was updated from v3.6.3 to v3.6.4, signaling a new version of the entry; this reflects a minor update to the page metadata rather than a change to the study content.SummaryDifference0.1%

- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedThe revision indicator on the page changes from v3.6.1 to v3.6.3. This reflects a minor site version update.SummaryDifference0.1%

- Check45 days agoChange DetectedRevision: v3.6.1 is now displayed, replacing v3.6.0. This update represents a minor page version upgrade that does not alter study content or results.SummaryDifference0.1%

- Check59 days agoChange DetectedRecruitment status note 'No longer looking for participants' was added, along with new navigation and help sections (How to Read a Study Record, Common Questions, How to Join a Study) and an 'Intervention/Treatment' heading; the revision tag changed from Revision: v3.5.5 to v3.6.0 and the 'Intervention / Treatment' heading formatting was removed.SummaryDifference0.5%

- Check66 days agoChange DetectedThe page revision tag was updated from v3.5.4 to v3.5.5, reflecting a small maintenance update to the page without changing study content.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Entinostat Efficacy in Eye Melanoma Clinical Trial page.